MRC Technology & Yabao Pharmaceuticals Announce Exclusive Partnership
MRC Technology and Yabao Pharmaceutical Co, Inc. recently announced an exclusive license agreement to discover, develop, and commercialize innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease.
Under the terms of the agreement, Yabao receives exclusive rights to discover, develop, and commercialise the therapeutics in China, Taiwan, and Hong Kong whilst MRC Technology retains rights in all other markets. Financial terms have not been disclosed.
Dr. Peng Wang, President R&D, Yabao Pharmaceutical Co. said “Yabao is pleased to be collaborating with MRC Technology, a leading UK research institute focused on improving the lives of patients through medical discovery. This opportunity for us to expand on leading research to develop innovative products is further evidence of Yabao’s growing commitment to partner the best science to treat serious diseases in China.”
Michael Dalrymple, Director, Business Development at MRC Technology, added “Parkinson’s is a debilitating and destructive disease. We are pleased to combine our expertise in early drug discovery and innovation with the significant resources that Yabao Pharmaceutical Co. can bring to developing ground breaking new medicines. Together we hope to achieve more to bring innovative treatments to patients and improve their quality of life.”
MRC Technology (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organizations within the academic, charity, biotechnology, and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules, and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialization, helping early discoveries progress to clinical application.
Yabao Pharmaceutical Co. (www.yabao.com.cn, is a leading Chinese pharmaceutical company with fully integrated development, manufacturing, and commercialization capabilities in China. The company undertakes strategic development of innovative pharmaceuticals in addition to a well-established business in modern traditional Chinese medicines and chemical generics. In addition to strong clinical and regulatory capabilities, Yabao has expertise in formulation and API production and meets good manufacturing practice (cGMP) requirements with a manufacturing site approved by US FDA and another awaiting inspection by the European agency.
Total Page Views: 1339
